Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis.

Abstract

A new nasal aerosol solution formulation of ciclesonide containing a hydrofluoroalkane propellant (CIC-HFA) delivered via a metered-dose inhaler is currently in clinical development as a potential treatment for allergic rhinitis (AR). This study evaluated the efficacy and tolerability of CIC-HFA 74- or 148-microgram doses compared with placebo in patients with perennial AR (PAR). Patients ≥12 years of age with a ≥ 2-year history of PAR were randomized in a placebo-controlled, double-blind, parallel-group, multicenter study to CIC-HFA 74 micrograms, CIC-HFA 148 micrograms, or placebo q.d. in the morning (A.M.) for 26 weeks. Change from baseline in reflective total nasal symptom score (rTNSS), instantaneous total nasal symptom score (iTNSS), and rhinoconjunctivitis quality-of-life questionnaire with standardized activities (RQLQ[S]) in patients with baseline RQLQ of ≥3.00 were evaluated for the first 6 weeks of treatment. Treatment-emergent adverse events (TEAEs) were monitored throughout the study. Eleven hundred eleven patients were randomized. CIC-HFA 74- and 148-microgram doses showed statistically significant improvements in rTNSS (least squares [LS] mean change, 0.70 and 0.54, respectively; p ≤ 0.001 versus placebo for both), iTNSS (LS mean change, 0.58 and 0.42, respectively; p < 0.05 versus placebo for both), and RQLQ[S] (LS mean change, 0.55 and 0.37, respectively; p < 0.01 versus placebo for both) from baseline. The overall incidence of TEAEs was comparable between the CIC-HFA treatment groups and placebo. In this study, once-daily treatment with CIC-HFA 74- or 148-micrograms showed statistically significant improvements in nasal symptoms of PAR. Both doses were well tolerated. Clinical trial registration URL and registration number: www.clinicaltrials.gov/ct2/show/NCT00953147.

• Authors: Dale Mohar, William E Berger, Craig Laforce, Gordon Raphael, Shailesh Y Desai, Holly Huang, Joseph Hinkle
• Journal: Allergy and asthma proceedings (Allergy Asthma Proc) 2012 Jan-Feb Vol. 33 Issue 1 Pg. 19-26 ISSN: 1539-6304 [Electronic] United States
• PMID: 22370530 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Allergic Agents
• Nasal Sprays
• Pregnenediones
• ciclesonide

Topics

• Adult
• Anti-Allergic Agents (administration & dosage, adverse effects)
• Drug Delivery Systems
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Nasal Sprays
• Pregnenediones (administration & dosage, adverse effects)
• Quality of Life
• Rhinitis, Allergic, Perennial (drug therapy, physiopathology)
• Treatment Outcome
• United States
• Young Adult